Procept Biorobotics Corp Stock Price, News & Analysis

PROCEPT BioRobotics (PRCT) reported strong Q4 2024 financial results with total revenue of $68.2 million, up 57% year-over-year. The company sold 60 new robotic systems in the US at an average price of $460,000. U.S. system revenue reached $27.6 million (+67%), while handpiece revenue grew to $29.3 million (+36%).

Full-year 2024 revenue was $224.5 million, representing 65% growth from 2023. The company achieved significant milestones including FDA 510(k) clearance for the HYDROS Robotic System and FDA-IDE approval for the WATER IV PCa prostate cancer study.

For 2025, PROCEPT projects revenue of approximately $320 million (+42% YoY) with an expected gross margin of 64.5%. Q4 2024 saw challenges with an acute saline shortage affecting 10-20% of Aquablation procedures.

PROCEPT BioRobotics (PRCT), a surgical robotics company specializing in urology solutions, has announced key upcoming events. The company will release its Q4 2024 financial results on February 25, 2025, after market close, followed by a conference call at 4:30 p.m. Eastern Time.

Additionally, management will participate in two significant healthcare conferences: the TD Cowen 45th Annual Healthcare Conference on March 4, 2025, at 1:10 p.m. ET, and the 2025 Leerink Partners Healthcare Conference on March 11, 2025, at 3:00 p.m. ET. Live webcasts and archived recordings of all events will be available on the company's investor relations website for at least 90 days.

PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urological solutions, has announced its participation in the 36th Annual Piper Sandler Healthcare Conference in New York City. The management team will deliver a presentation on Wednesday, December 4 at 8:30 a.m. Eastern Time.

The presentation will be accessible through a live webcast on the company's investor relations website. Interested parties can access the webcast recording for up to 90 days after the event through the company's website at https://ir.procept-biorobotics.com.

PROCEPT BioRobotics (NASDAQ: PRCT) has announced the pricing of its public offering of 1,923,076 shares of common stock at $91.00 per share, aiming to raise approximately $175 million in gross proceeds. A selling stockholder has granted underwriters a 30-day option to purchase up to an additional 288,461 shares. The offering, expected to close around October 31, 2024, is being managed by BofA Securities, Piper Sandler, and Morgan Stanley. The company will not receive proceeds from shares sold by the selling stockholder.

PROCEPT BioRobotics (NASDAQ: PRCT), a surgical robotics company specializing in urology solutions, has announced a $175 million public offering of common stock. A selling stockholder will grant underwriters a 30-day option to purchase up to an additional $26.25 million of shares. The company will not receive proceeds from the selling stockholder's share sale. BofA Securities, Piper Sandler and Morgan Stanley are acting as joint book-running managers. The offering will be conducted through a prospectus supplement and accompanying prospectus filed with the SEC.

PROCEPT BioRobotics reported strong Q3 2024 results with total revenue of $58.4 million, up 66% year-over-year. U.S. revenue grew 62% to $52.2 million, while international revenue increased 122% to $6.2 million. The company sold 45 robotic systems in the U.S. at an average price of $432,000. Gross margin reached a record 63.2%, up from 53.8% in the prior year. The company increased its 2024 guidance, projecting revenue of $222.5-223.0 million and improved its adjusted EBITDA loss forecast to $60.0 million. Cash position remained strong at $199.8 million as of September 30, 2024.

PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology solutions, has announced its plans to release third quarter 2024 financial results on October 28, 2024, before the market opens. The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the results.

Interested parties can access the call through a webcast link or a dial-in registration for sell-side research analysts. The live audio webcast and an archived recording will be available on the company's investor relations website. The webcast replay will be accessible for at least 90 days after the event.

PROCEPT BioRobotics (Nasdaq: PRCT) has received FDA approval to initiate a pivotal randomized clinical study for prostate cancer treatment. The WATER IV PCa trial will compare Aquablation therapy to radical prostatectomy in men with Grade Group 1 to 3 localized prostate cancer. This global multicenter study will enroll up to 280 patients across 50 centers, with a 10-year follow-up period.

The FDA has also granted Breakthrough Device Designation for Aquablation therapy in prostate cancer treatment. The study's co-primary endpoint focuses on morbidity at six months, with longer-term follow-up assessing treatment-related harm reduction and oncologic events. This trial could potentially revolutionize localized prostate cancer treatment for millions of men.

PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology solutions, has announced its participation in the 2024 Wells Fargo Healthcare Conference in Boston. The company's management team is scheduled to present on Wednesday, September 4, 2024, at 1:30 p.m. Eastern Time.

Investors and interested parties can access a live webcast of the presentation through the company's website at https://ir.procept-biorobotics.com. The webcast will also be archived for at least 90 days after the event, allowing for later viewing. This presentation offers an opportunity for PROCEPT BioRobotics to showcase its innovative urological solutions and connect with healthcare industry professionals and investors.